Literature DB >> 15072117

How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information.

Eric Schirm1, Taco B M Monster, Robin de Vries, Paul B van den Berg, Lolkje T W de Jong-van den Berg, Hilde Tobi.   

Abstract

PURPOSE: Pharmacy-dispensing data are valuable sources of drug information, but the population that is covered by the pharmacies is often difficult to determine. We evaluated two methods using drug utilisation information to estimate the population size: a drug-use-based extrapolation of a known part of the population and a capture-recapture estimation without any prior knowledge of the population.
METHODS: Using pharmacy-dispensing data of three towns with known populations in the Netherlands, we estimated age-and-sex specific population sizes by extrapolating the proportion of drug-using inhabitants. In addition, we applied two-source and three-source capture-recapture models with all combinations of the following drug groups as different sources: anti-asthmatics, analgesics, antibiotics and anti-histamines.
RESULTS: Drug-use-based extrapolation resulted in the best estimates with the least variability. All capture-recapture models provided underestimations of the true population. Three-source capture-recapture resulted in better average estimates than two-source capture-recapture, but also had more variability.
CONCLUSIONS: If a part of the population is known, and if there is reason to assume that drug utilisation patterns do not vary within the region, it is best to use drug-use-based extrapolation. In all other situations capture-recapture may be considered, with as main limitation that we found all models to underestimate the population considerably.

Mesh:

Year:  2004        PMID: 15072117     DOI: 10.1002/pds.882

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

1.  Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study.

Authors:  Adrianne Faber; Ron J Keizer; Paul B van den Berg; Lolkje T W de Jong-van den Berg; Hilde Tobi
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

2.  The gap between evidence-based medicine and daily practice in the management of paediatric asthma. A pharmacy-based population study from The Netherlands.

Authors:  Tjalling W de Vries; Hilde Tobi; Eric Schirm; Paul van den Berg; Eric J Duiverman; Lolkje T W de Jong-van den Berg
Journal:  Eur J Clin Pharmacol       Date:  2005-12-20       Impact factor: 2.953

3.  Differences between drug utilisation estimates based on pharmacy sales and on purchases by the resident population.

Authors:  Anders Ekedahl; Gunnar Lindberg
Journal:  Pharm World Sci       Date:  2005-12

4.  The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus.

Authors:  René Lub; Petra Denig; Paul B van den Berg; Klaas Hoogenberg; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

5.  Prescribed doses of inhaled steroids in Dutch children: too little or too much, for too short a time.

Authors:  Eric Schirm; Tjalling W de Vries; Hilde Tobi; Paul B van den Berg; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

6.  The pharmacists' potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma.

Authors:  J F M van Boven; E G Hiddink; A G G Stuurman-Bieze; C C M Schuiling-Veninga; M J Postma; S Vegter
Journal:  Int J Clin Pharm       Date:  2013-07-26

7.  Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.

Authors:  Adrianne Faber; Marcel L Bouvy; Linda Loskamp; Paul B van de Berg; Toine C G Egberts; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

8.  Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough.

Authors:  Stefan Vegter; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

9.  Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries.

Authors:  Antje Neubert; Yingfen Hsia; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Gerd Glaeske; Kari Furu; Helle Kieler; Mette Nørgaard; Antonio Clavenna; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

10.  The effects of antitussive treatment of ACE inhibitor-induced cough on therapy compliance: a prescription sequence symmetry analysis.

Authors:  Stefan Vegter; Pieter de Boer; Klaas Willem van Dijk; Sipke Visser; Lolkje T W de Jong-van den Berg
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.